BioMarin Enrolls First Patient in Phase 1/2 Trial of Gene Therapy Drug Candidate BMN 270 for the Treatment of Hemophilia A
September 28, 2015 16:09 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Sept. 28, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has enrolled the first patient in a Phase 1/2 trial for BMN 270, an...
BioMarin Announces Kuvan(R) (sapropterin dihydrochloride) Patent Challenge Settlement
September 18, 2015 16:30 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Sept. 18, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that it has entered into a settlement agreement with Dr. Reddy's Laboratories, Inc....
BioMarin to Attend Upcoming Investor Conferences in September
September 02, 2015 08:00 ET
|
BioMarin Pharmaceutical Inc.
Morgan Stanley Global Healthcare Conference on September 16 in New York
J.P. Morgan 6th Annual U.S. All Stars Conference on September 16 in London
Bank of America Merrill Lynch Global...
BioMarin Launches kNOWyourDuchenne, Comprehensive Program for Patients With Duchenne Muscular Dystrophy to Understand Their Genetic Mutation
September 01, 2015 08:30 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Sept. 1, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the introduction of kNOWyourDuchenne, a program to help families and physicians obtain...
BioMarin Announces Two Oral and 19 Poster Presentations at the Society for the Study of Inborn Errors of Metabolism 2015 Annual Meeting
August 31, 2015 08:30 ET
|
BioMarin Pharmaceutical Inc.
Oral Presentations Include Long-Term Safety and Efficacy with Pegvaliase for Control of Blood Phenylalanine in Adults with PKU and a Review of the Ongoing Development Program for Reveglucosidase...
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin
August 24, 2015 07:00 ET
|
BioMarin Pharmaceutical Inc.
Talazoparib is a Highly-Potent PARP Inhibitor in Phase 3 Development for the Treatment of BRCA-Mutated Breast Cancer
Clinical Activity Observed in Multiple Oncology Opportunities with...
BioMarin Receives Rare Pediatric Disease Designation From FDA for Drisapersen for the Potential Treatment of Duchenne Muscular Dystrophy
August 19, 2015 16:05 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Aug. 19, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease...
Forbes Ranks BioMarin 10th Most Innovative Company in the World
August 19, 2015 10:37 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Aug. 19, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it has been ranked 10th on Forbes magazine's 2015 list of the "World's Most...
BioMarin Announces Second Quarter 2015 Financial Results and Company Update
August 03, 2015 16:02 ET
|
BioMarin Pharmaceutical Inc.
- In First Six Months of 2015 Vimizim Sales Top $104 million and Total BioMarin Revenue Grows 32% Y/Y
- First Patients Enrolled in 4th Cohort of Phase 2 Study of Vosoritide for the Treatment of...
BioMarin Joins the NASDAQ-100 Index
July 27, 2015 08:00 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., July 27, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that it will become a component of the NASDAQ-100 Index® (NASDAQ:NDX), the...